Pharmaceutical Technology

JULY 14, 2022

Such movements have enabled pharmaceutical companies to increase their focus on rare diseases, and the number of orphan drug launches is steadily increasing. The choice of where to launch an orphan drug is an important and difficult decision. The choice of where to launch an orphan drug is an important and difficult decision.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Hospitals 59

pharmaphorum

APRIL 14, 2022

million price tag. The gene therapy has already been approved for marketing in the EU and UK, where it was launched at a cost of around $1.7 bluebird pulled it off the market last year however and retreated from the European market, saying the pricing and reimbursement environment was too hostile to make its business there viable.

FDA 64

FDA 64

pharmaphorum

AUGUST 18, 2022

The US approval comes three years after Zynteglo (betibeglogene autotemcel) was approved for the same indication in Europe, and subsequently withdrawn after bluebird concluded that it wasn’t possible to build a commercially viable business for the gene therapy as the pricing and reimbursement environment there was too “hostile.”

FDA 52

FDA Insurance 52

The Social Pharmacist

AUGUST 2, 2022

When you don’t control the environment that drives your revenue, you wind up with a hefty advertising bill to generate traffic. Paid Search Traffic: It comes from a paid search campaign launched on a search engine like Google or Bing. . Try to insert meta-data details that include title tags to your website pages with descriptions.

52

52

pharmaphorum

AUGUST 26, 2022

million for the one-shot therapy – in other words, after any discounts that it may offer or outcomes-based agreements – aiming to launch first in Germany followed by France. BioMarin has said Roctavian will be available at a ‘net’ price of around €1.5 million spread over five years. million spread over five years.

FDA 111

FDA 111

PharmaShots

MARCH 9, 2023

Since its launch in 2016, Tivic Health has obtained three regulatory clearances for ClearUP, including FDA 510(k), FDA De Novo, and CE Mark, four patents, and numerous awards. As a leader, she wants to foster an inclusive environment where everyone can be themselves and work together to make a significant difference for patients.

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

Pharmaceutical Technology

MARCH 17, 2023

On 16 March, Watt spoke at GlobalData webinar titled “Pharma [POLI]: Market Access Risk Outlook”, providing a current outlook on the pharmaceutical pricing and reimbursement environments around the world, including key reforms, risks and opportunities. GlobalData is the parent company of Pharmaceutical Technology.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102